Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospicare Inc. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality of life have seriously deteriorated. There have been a few studies that showed an effect for pain control by hyperthermia (heating the patient's body). However, there are several limitations in conventional hyperthermia.
In a previous pilot study (NCT02150135), we found the improvement of quality of life, function, and symptom.
From this background, the investigators tried to show the effect of "Oncothermia" with conventional chemotherapy for pain control, increasing quality of life, and anti-tumor treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oncothermia | Experimental | Patients with oncothermia treatment and palliative chemotherapy |
|
| Control | Active Comparator | Patients with palliative chemotherapy only |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oncothermia | Other | Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia. |
|
| Measure | Description | Time Frame |
|---|---|---|
| European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| change of opioid use amount | 3 months | |
| change of pain score (VAS score) | 3 months | |
| Adverse effect |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jin-Hyeok Hwang, MD PhD | Contact | +82-31-787-7017 | woltoong@snu.ac.kr | |
| Jaihwan Kim, MD | Contact | +82-31-787-7075 | drjaihwan@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Jin-Hyeok Hwang, MD PhD | Seoul National University Bundang Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Bundang Hospital | Recruiting | Seongnam-si | Gyeonggi-do | 463-707 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000627770 | folfirinox |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| FOLFIRINOX or Gemcitabine based chemotherapy | Drug | As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients. |
|
| 3 months |
| D004066 |
| Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |